Reinsurance Disputes Over Aggregation of Losses

Introduction

Reinsurance disputes over aggregation of losses arise when an insurer and its reinsurer disagree about whether multiple claims should be treated as one loss or as several separate losses under a reinsurance contract. The issue is important because the number of losses may determine how much the reinsurer must pay.

In biotechnology, one manufacturing defect, contaminated production batch, clinical-trial incident, or defective therapy may affect numerous patients or products. The insurer may seek to aggregate these claims into a single event to access a larger reinsurance limit. The reinsurer may argue that the claims arise from separate causes, locations, batches, or incidents and should be treated independently.

The legal question is primarily one of contractual interpretation: what connecting factor does the reinsurance wording require before separate claims can be combined?

Legal Tests for Aggregation

The result depends on the exact wording of the reinsurance contract. Common aggregation clauses use terms such as “one event,” “one occurrence,” “originating cause,” or “series of losses attributable to one source.”

The distinction is significant:

One event: Usually requires a sufficiently significant causal connection to a discrete happening.

One originating cause: May permit a broader inquiry into a continuing condition or common underlying cause.

One occurrence: Must be interpreted in the policy’s context; courts consider whether the losses possess sufficient unity to be treated as one occurrence.

Aggregation can affect deductibles, attachment points, policy limits, and the number of reinstatements available. The court must interpret the contract as a whole rather than assume that all claims arising from a common background should be combined.

publications.parliament.uk+1

Important Case Laws

1. AXA Reinsurance (UK) plc v. Field, [1996] 1 WLR 1026

The House of Lords distinguished “event” from “originating cause.” An event is generally a happening at a particular time and place, while an originating cause may be a broader continuing state of affairs. The case is important because the wording of an aggregation clause determines how widely losses may be combined.

Apex+1

2. Scott v. Copenhagen Reinsurance Co. (UK) Ltd., [2003] EWCA Civ 688

The Court of Appeal explained that aggregation under an “arising out of one event” clause requires a significant causal connection. A weak or remote connection is insufficient. This is relevant where a reinsurer argues that separate biotech claims cannot be combined merely because they share a general background, such as the same manufacturer or technology.

Bailii

3. AIG Europe Ltd v. OC320301 LLP, [2016] EWCA Civ 367

The Court considered whether losses arising from a common cause could be aggregated. It reinforced the distinction between “event” and “originating cause,” holding that broader causal wording may allow aggregation based on a common underlying failure. The case was subsequently considered by the Supreme Court in AIG Europe Ltd v. Woodman, [2017] UKSC 18.

Bailii

4. Lloyds TSB General Insurance Holdings Ltd v. Lloyds Bank Group Insurance Co. Ltd., [2003] UKHL 48

The House of Lords explained that aggregation clauses allow separate losses to be treated as one when they are linked by the unifying factor specified in the contract. The breadth of the clause depends on the precise wording selected by the parties.

publications.parliament.uk

Application to Biotechnology

Suppose a biologics manufacturer supplies a contaminated ingredient to several production facilities. If the reinsurance wording refers to one “originating cause,” the common ingredient or systemic contamination may support aggregation. If it requires one discrete “event,” separate contamination incidents at different times may be treated separately unless the required causal connection is established.

The same analysis applies to gene-therapy adverse-event claims, defective diagnostic kits, or clinical-trial losses. The contract’s wording, facts, and causal evidence determine the result.

Conclusion

Reinsurance aggregation disputes concern contractual interpretation and the required connection between multiple losses. Courts distinguish a discrete event from a broader originating cause and require a meaningful causal link. The cited cases provide influential common-law guidance, but they are not biotech-specific decisions. In biotechnology disputes, aggregation must be assessed through the exact reinsurance clause, the nature of the underlying losses, and the evidence connecting them.